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Abstract
Background: There are an increasing number of patients suffering from fatty liver caused by type 2 diabetes. We
intended to study the preventive and therapeutic effect of L-carnitine (LC) on nonalcoholic fatty liver disease
(NAFLD) in streptozotocin (STZ)-induced type 2 diabetic mice and to explore its possible mechanism.
Methods: Thirty male Kungming mice were randomly divided into five groups: control group, diabetic group, pre-
treatment group (125 mg/kg BW), low-dose (125 mg/kg BW) therapeutic group and high-dose (250 mg/kg BW)
therapeutic group. The morphology of hepatocytes was observed by light and electron microscopy. LC and ALC
(acetyl L-carnitine) concentrations in the liver were determined by high-performance liquid chromatography
(HPLC). Moreover, liver weight, insulin levels and free fatty acid (FFA) and triglyceride (TG) levels in the liver and
plasma were measured.
Results: Average liver LC and ALC levels were 33.7% and 20% lower, respectively, in diabetic mice compared to
control mice (P < 0.05). After preventive and therapeutic treatment with LC, less hepatocyte steatosis, clearer crista
and fewer glycogen granules in the mitochondria were observed. Decreased liver weight, TG levels, and FFA
concentrations (P < 0.05) in the liver were also observed after treatment with LC in diabetic mice. Moreover, liver
LC and ALC levels increased upon treatment with LC, whereas the ratio of LC and ALC decreased significantly (P <
0.01).
Conclusion: LC supplements ameliorated fatty liver in type 2 diabetic mice by increasing fatty acid oxidation and
decreasing the LC/ALC ratio in the liver. Therefore, oral administration of LC protected mitochondrial function in
liver.
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Introduction
Nonalcoholic fatty liver disease (NAFLD), one of the
most common complications of type 2 diabetes, is char-
acterized by an increase in fatty acids, triglycerides, and
cholesterol levels [1] and fat accumulation in the liver.
Among type 2 diabetes patients, 50%-70% of individuals
were diagnosed with NAFLD; in obese patients, that
value increases to 95% [2]. Recent studies have shown
that NAFLD and insulin resistance [3] were involved in
metabolic syndrome (MS), especially in fatty acid
metabolic disorder, which primarily occurred in obese
and type 2 diabetes patients [4]. Prolonged exposure to
free fatty acids damages pancreatic b-cells and hepato-
cytes [5]. Furthermore, excessive fat accumulation in the
liver damages mitochondria, which are the primary
cellular sites for fatty acid utilization [6,7]. Current
general therapies to treat the early stages of fatty liver
disease include lifestyle modification approaches such as
exercise and weight loss with diet. The goals of these
strategies are to normalize aminotransferase levels and
to reduce liver fat levels and inflammation. However,
none of these strategies specifically improve mitochon-
drial function in type 2 diabetes patients. The aim of the
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improve mitochondrial function in fatty liver disease in
type 2 diabetes patients.
L-Carnitine (L-b-hydroxy-g-N-trimethylaminobutyric
acid [8,9]) (LC) is present in the free or acyl-carnitine
form in the plasma [10]. LC plays an important role in
lipid metabolism; it acts an essential cofactor for the b-
oxidation of fatty acids by facilitating the transport of
long-chain fatty acids across the mitochondrial mem-
brane as acyl-carnitine esters. It can activate carnitine
palmityl transferase-1 (CPT-1), the key enzyme in fatty
acid oxidation [11]. Furthermore, because LC shuttles
acetyl groups from inside to outside the mitochondrial
membrane, it increases the CoA-SH/acetyl-CoA ratio in
the mitochondrion by forming Acetyl L-carnitine (ALC)
with the help of carnitine acetyltransferase (CAT)
[12,13], whose activity relieves inhibition of the PDH
complex and increases glycometabolism [14-16].
According to a previous study, significantly reduced lac-
tate plasma levels suggested that LC can also stimulate
t h ea c t i v i t yo fp y r u v a t ed e h y d r o g e n a s e( P D H )[ 1 7 ] ,
whose activity is deficient in type 2 diabetic patients
[18]. These results demonstrated that LC can act as a
carrier of acetyl groups from the mitochondria to the
cytosol [15,19]. In addition, LC was defined as a biomar-
ker to assess the function of the mitochondria [20]. Evi-
dence showed that a combination of nutrients, including
LC, can improve mitochondrial dysfunction in the liver
of type 2 diabetic Goto-Kakizaki rats [21]. Recently, Kar-
anth et al. proposed that LC supplements enhanced the
activity of mitochondrial enzymes such as CPT-1 and
the respiratory chain enzymes [22]. Based on the evi-
dence described above, we explored the effects of LC on
NAFLD caused by type 2 diabetes.
The earliest study of the effect of LC on steatohepatitis
was performed by Bowyer et al. in 1988 [23]. They claimed
that LC deficiency was not the major cause of liver steato-
sis. However, a recent study showed that LC played a role
in reducing steatosis in patients with hepatitis C treated
with IFN alpha and ribavirin [24]. LC supplements in
patients with NASH (non-alcoholic steatohepatitis) greatly
improved glucose plasma levels, lipid profiles and histolo-
gical manifestations [25]. However, none of these studies
focused on the effect of LC on NAFLD caused by type 2
diabetes, especially in diabetic mice.
T h ea i mo ft h ep r e s e n ts t u d yw a st oe x p l o r et h ep r e -
ventive and therapeutic effect of LC on NAFLD in
streptozotocin (STZ)- and diet-induced type 2 diabetic
mice with regard to morphological and biochemical
aspects. We also intended to determine whether its
effect was due to an improvement in the mitochondrial
function of hepatocytes to provide theoretical evidence
for LC as a clinical therapy for NAFLD.
Materials and methods
Animals
Male Kunming SPF 3-week-old mice (Institute for Drug
Control of Qingdao, China), weighing between 15 g and
17 g were used. They were fed a diet containing 59%
basic mice feed, 20% sugar, 18% lard, and 3% egg yolk.
They had free access to food and water in an animal
room maintained at 22 ± 3°C. The protocols used for
handling the mice were approved by the Qingdao Uni-
versity Center for human functional experiment of the
medical college Animal Care Committee and were in
accordance with the guidelines set by the National Insti-
tutes of Health Guide for Care and Use of Laboratory
Animals.
The animals were randomly divided into five groups: a
control group (only high-calorie diet), a diabetic group,
a preventive treatment group (125 mg/kg, intragastric, i.
g.) and two therapeutic groups (250 mg/kg, 125 mg/kg,
i.g.). At the age of 6 and 9 weeks, two low doses of STZ
(100 mg/kg, i.p., provided by Sigma) prepared in 0.1 N
citrate buffer at pH 4.5 were given to mice in the dia-
betic, preventive and therapeutic groups. Age-matched
control group mice were injected with NS (normal sal-
ine) alone. Mice with fasting blood glucose levels above
12 mmol/L and insulin levels within the average range
of the control group were considered type 2 diabetic
mice.
Drugs
LC (provided by Northeast Pharmaceutical Factory,
China) was dissolved in double distilled water. In the
study of the preventive effect of LC on hepatopathy in
type 2 diabetic mice, oral administration of LC (low-
dose, 125 mg/kg, i.g.) began on the day the mice were
provided the high-calorie diet (3 weeks of age). LC was
administrated to the therapeutic groups after they had
developed diabetes (9 weeks of age). The two therapeu-
t i cg r o u p so fd i a b e t i cm i c ew e r eg i v e nd i f f e r e n to r a l
doses of LC, a high-dose (250 mg/kg, i.g.) and a low-
dose (125 mg/kg, i.g.). All the administrations were
g i v e no n c ead a yu n t i lt h em i c ew e r e1 2w e e k so fa g e .
In addition, LC was administrated to mice in the pre-
ventive and therapeutic groups 30 min before samples
were collected. Mice in the control group were given
the same volume of saline. (Table 1: experimental
design)
Preparation of plasma and liver homogenates
All mice were sacrificed at 12 weeks of age. Blood sam-
ples were collected via retro-orbital bleeding. Fresh
livers were observed and weighed. Livers were homoge-
nized, and 1 ml of supernatant was collected and stored
at -20°C until analyzed.
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Body weights were measured once a week with an elec-
tric balance (Mettler Toledo, PL1501-S, Shanghai,
China). Whole explanted livers were weighed on an
electric analytical balance (Mettler Toledo, AL104,
Shanghai, China). Relative liver weights (per body
weight) were calculated (relative liver weight: liver
weight/body weight×100%).
Liver morphology
Samples were washed with phosphate-buffered saline
and fixed with 4% paraformaldehyde. Longitudinal sec-
tions (10 μm) were cut in a microtome (model CM1900;
Leica, Germany), placed on microscope slides and
stained with oil red O. Image Pro Plus 6.0 was used to
quantify the size of the lipid droplets. For electron
microscopy analysis, liver apexes were processed accord-
ing to routine procedures [26]. Ultrastructural changes
in the liver were observed by transmission electron
microscopy (TEM) (provided by JEOL, 1200EX).
Measurement of triglyceride and FFA concentrations in
the plasma and liver
Liver free fatty acid levels were estimated by a Cu-col-
orimetric method using a non-esterified fatty acid assay
kit (provided by Applygen Technologies Inc. Beijing,
China). The results are expressed in absorbance values.
TG levels in the plasma and liver were determined by
photoelectric colorimetry using an automatic biochem-
ical analyzer (Saturno-300, provided by CRNOY S.R.I
Company, Italy).
LC and ALC concentrations in the liver
The concentrations of LC and ALC in the liver were
analyzed by high-performance liquid chromatography
(HPLC). This method was first established in our lab
[27]. A Waters2695 High Performance Liquid Chroma-
tography system (Waters, America) equipped with a
Hypersil C18 column (5 μm particle size, 200 mm
length, 4.6 mm internal diameter) and a Waters474
fluorescence detector (Waters, America) was used.
Statistical analysis
The data are expressed as the mean ± SD. Statistically
significant differences between groups were assessed by
analysis of variance (one-way ANOVA), repeated mea-
sures and multivariate tests followed by LSD. A P value
of less than 0.05 was considered statistically significant.
Results
Changes in blood glucose and plasma insulin levels
Blood glucose levels were 197% higher in the diabetic
group than in the control group (control+NS 6.35 ±
0.63 mmol/L vs. DM+NS 18.9 ± 6.04 mmol/L, P =
0.001). Plasma insulin levels in diabetic mice were nor-
mal (control+NS 12.94 ± 0.91 mIU/L vs. DM+NS 11.56
± 1.09 mIU/L, P = 0.503).
Effects of LC on changes in body weight in
STZ-treated mice
At the 8th week, the average body weight of the preven-
tive group was 14.6% lower than in the control group
(control group 40.617 ± 2.919 g vs. preventive group
34.7 ± 2.571 g, P = 0.016). From the 10th week on, sig-
nificant differences in body weight between the preven-
tive and diabetic groups were apparent (P = 0.012). At
the end of the 12th week, mice in the two therapeutic
groups were heavier than those in the diabetic group
(Figure 1).
Lipid metabolism
All diabetic mice had higher liver FFA (+22.6%) and TG
(+402.6%) levels, plasma TG levels (+225%), liver weight
(+84.6%) and relative liver weight (+50%).
As shown in table 2, after 3 and 6 weeks of treatment
with oral LC, liver FFA levels decreased in the pre-treat-
ment, high-dose and low-dose therapeutic groups. There
was no significant difference in FFA levels between
these mice and mice in the control group (P>0.175). LC
therapy also remarkably decreased liver TG levels (DM
+NS vs. pre-treatment P < 0.01, DM+NS vs. high-dose
P < 0.01, DM+NS vs. low-dose P < 0.05). Moreover, the
mean plasma TG levels were 1.2 ± 0.1 mmol/L in the
control group and 3.9 ± 2.3 mmol/L in the diabetic
group. LC caused a decreased in plasma TG levels, espe-
cially in the high-dose and preventive treatment groups
(high-dose therapeutic group 1.625 ± 0.399 mmol/L,
preventive group 1.713 ± 0.636 mmol/L).
The average liver weight in the diabetic group was
44.6% higher than in the control group (table 2) (control
0.0439 ± 0.0050 vs. DM+NS 0.0635 ± 0.0103, P < 0.01).
After administrating LC for prevention and treatment
purposes, the liver weight significantly decreased. After
treatment with LC, the relative liver weight also
decreased, both in the high-dose therapeutic group
(0.0489 ± 0.0020, P < 0.01 vs. diabetic group) and in the
Table 1 Experimental design
Group 3 weeks old 6 weeks old 9 weeks old
Control HFD+NS HFD+NS (CB) HFD+NS (CB)
DM+NS HFD+NS HFD+NS (STZ) HFD+NS (STZ)
Pre-treat HFD+LC HFD+LC (STZ) HFD+LC (STZ)
DM+LC(L) HFD+NS HFD+NS (STZ) HFD+LC (STZ)
DM+LC(H) HFD+NS HFD+NS (STZ) HFD+LC (STZ)
Control: control group (n = 6), DM+NS: diabetic group (n = 6), pre-treatment:
preventive group (n = 6), DM+LC (L): low-dose therapeutic group (125mg/kg,
i.g.) (n = 6), DM+LC (H): high-dose therapeutic group (250mg/kg, i.g.) (n = 6).
All administrations of LC were given orally. HFD: high-fat diet; STZ:
streptozotocin; LC: L-carnitine; CB: citrate buffer. At the age of 6 and 9 weeks,
mice were injected twice with STZ or CB, respectively.
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vs. diabetic group). Furthermore, the effect of LC on
liver weight was dose dependent.
LC and ALC system
Mean LC and ALC levels were 33.7% and 20% lower in
the diabetic group than in the control group, respec-
tively (LC P = 0.033) (table 2). Mice in the preventive
and therapeutic groups expressed higher levels of LC
than those in the diabetic group, which were not signifi-
cantly different than those of the control group. In total,
the exogenous administration of LC could compensate
for the deficiency of both LC and ALC in type 2 diabetic
mice. Interestingly, average LC concentrations in the
high-dose therapeutic group were lower than in the
low-dose therapeutic group, whereas the high-dose ther-
apeutic group expressed the highest ALC levels among
t h ef i v eg r o u p s( t a b l e2 ) .T h e r ew e r en os i g n i f i c a n td i f -
ferences in the LC/ALC ratio between the control and
diabetic groups (Control+NS 16.9455 ± 4.7270 μmol/L,
DM+NS 16.5659 ± 5.9218 μmol/L), whereas the ratio
decreased after LC treatment. Among all the therapeutic
groups, the ratio in the high-dose group was the lowest.
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Figure 1 Effects of LC on the changes in body weights of STZ-treated mice. control: control group (n = 6), DM+NS: diabetic group (n = 4),
pre-treatment: preventive group (n = 3), DM+LC (H): high-dose therapeutic group (n = 4), DM+LC (L): low-dose therapeutic group (n = 3). All
values are expressed as the mean ± S.E. using the repeated measures method. *P < 0.05, **P < 0.01 (compared to control group),
#P < 0.05,
##P
< 0.01 (compared to diabetic group).
Table 2 Metabolic parameters
Variable Control DM+NS Pre-treatment DM+LC(L) DM+LC(H)
Body Weight (g) 44.4 ± 3.4 40.1 ± 2.1 32.0 ± 2.8
××## 40.3 ± 2.0 41.8 ± 5.6
Liver weight (g) 1.3 ± 0.3 2.4 ± 0.5** 2.0 ± 0.4* 1.9 ± 0.3*
# 1.8 ± 0.2
#
Relative liver weight 0.04 ± 0.01 0.06 ± 0.01** 0.06 ± 0.01 0.05 ± 0.00
# 0.05 ± 0.00
##
FFA in liver (L/g·cm) 1.7 ± 0.1 2.0 ± 0.3* 1.8 ± 0.2 1.9 ± 0.3 1.8 ± 0.1
TG in liver (mmol/L) 0.23 ± 0.04 1.16 ± 0.6** 0.34 ± 0.2
## 0.55 ± 0.09
# 0.48 ± 0.1
##
TG in plasma (mmol/L) 1.2 ± 0.1 3.9 ± 2.3** 1.7 ± 0.6 2.2 ± 1.0 1.6 ± 0.4
LC in liver (μmol/L) 16.9 ± 3.4 11.2 ± 2.6* 12.1 ± 3.1 14.9 ± 1.9 12.6 ± 4.1
ALC in liver (μmol/L) 1.0 ± 0.2 0.8 ± 0.3 1.0 ± 0.7 1.4 ± 0.2 2.3 ± 0.9**
##
LC/ALC 16.9 ± 4.7 16.6 ± 5.9 15.4 ± 6.6 11.3 ± 2.8 5.6 ± 1.5**
##
Control: control group, DM+NS: diabetic group, pre-treatment: preventive group, DM+LC (L): low-dose therapeutic group, DM+LC (H): high-dose therapeutic
group. All values are expressed as the mean ± S.E. using the repeated measures method. *P < 0.05, **P < 0.01 (compared to control group),
#P < 0.05,
##P < 0.01
(compared to diabetic group).
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cant (P < 0.01).
Morphological changes in the liver
T h es i z eo ft h el i v e r si nt h ed i a b e t i cm i c ew a sg e n e r a l l y
larger than in control mice. In general, the livers of dia-
betic mice were yellow in color with numerous particles
on the surface and were much harder than normal
livers. After treatment with LC, the size of the livers
decreased, and the surfaces became smoother.
To analyze fat deposits in liver cells, liver sections
were stained with oil red O. Obvious liver fatty degen-
eration and piecemeal necrosis of hepatocytes were
observed in the diabetic group by LM (Figure 2-a).
There were many red lipid deposits (stained by red oil
O) in the hepatocytes of the diabetic group. As shown
in Figure 2-I, the number of lipid deposits decreased
with increasing doses of LC, especially in the preventive
and high-dose therapeutic groups. Images from these
two groups are very similar to those of the control
g r o u p .A ss h o w ni nF i g u r e2 - I I ,t h ep e r c e n t a g eo ft h e
lipid profile area to total area in diabetic mice was
5.44%, which is consistent with a clinical diagnosis of
NAFLD [28]. Although the lipid area in the low-dose
therapeutic mice was still fairly high (2.0 ± 0.52%), it
was significantly lower than in the diabetic mice (P <
0.01). With the increasing dose of LC or the extension
of treatment time, the lipid area percentage (Figure 2-b)
decreased by 95.8% in the high-dose therapeutic group
and 92.6% in pre-treatment group. There was no signifi-
cant difference in lipid area percentage between mice in
the LC treatment groups and the control group.
Obvious mitochondrial swelling, crista disorder and an
increase in electron density were observed by TEM in
t h ed i a b e t i cg r o u p( F i g u r e3 B )c o m p a r e dt ot h ec o n t r o l
group (Figure 3A). In addition, there were more glyco-
g e ng r a n u l e si nt h ec y t o p l a s mi nt h ed i a b e t i cg r o u p ,
which is a characteristic of type 2 diabetes. Morphologi-
cal damage of the mitochondria recovered after adminis-
tration of LC. The LC groups possessed clearer crista
(Figure 3C-E) and rough endoplasmic reticulum (Figure
3C) with dense granules.
Discussion
Model
Results from another study in our lab clearly indicated
that we successfully created type 2 diabetic mice
through a combination of a high-calorie diet and two
low-dose STZ injections. Although the insulin levels of
the diabetic mice were normal, the blood glucose levels
were high. These results were consistent with character-
istics of type 2 diabetes [29]. To verify the diagnosis of
NAFLD, a liver biopsy, which is the gold standard [28],
was performed. The biopsy revealed that the lipid area
was above 5% (Figure 2-b). Moreover, liver TG and FFA
levels of diabetic mice were increased. All of these
results are consistent with characteristics of type 2 dia-
betes: high glucose, insulin resistance, hyperlipidemia
and obesity. Therefore, type 2 diabetes can be induced
in mice by a combination of a high-calorie diet and two
low-dose STZ injections to study the pathophysiological
changes caused by diabetes or to evaluate the therapeu-
tic effects of LC on fatty liver in type 2 diabetes.
Morphological changes
The prevalence of NAFLD is high in obesity, diabetes,
high-calorie diet and hyperlipidemia [30]. Our research
confirmed the characteristics of NAFLD in diabetic
mice. The gross appearance of the liver improved upon
treatment with LC; the liver decreased in size and
appeared brighter and less greasy. These changes were
partly observed by quantifying the lipid droplets by LM
(Figure 2-b). Therefore, it could be concluded that LC
improved steatosis of the liver in type 2 diabetic mice.
There was no obvious fibrosis in these images, suggest-
ing that the diabetic mice in our study only suffered
from fatty liver and had not yet developed cirrhosis.
Therefore, this process was reversible. In addition, there
were large areas of glycogen granules in the cytoplasm
of diabetic mice, which is the electron microscopy fea-
ture of type 2 diabetes. Large numbers of granules
attached to the rough endoplasmic reticulum in the pre-
ventive group, also suggested that cell function signifi-
cantly improved upon administration of LC. To ensure
the therapeutic effect of LC from a general perspective,
body weight and relative liver weight values were evalu-
ated. These results suggest that LC stimulated fat meta-
bolism and improved mitochondrial function in the
liver.
Mechanisms of liver dysfunction caused by type 2
diabetes mellitus
It was hypothesized that in type 2 diabetes mellitus,
there was a shift in substrate utilization from carbohy-
drates to lipids [31]. From what has been discussed
above, we knew that type 2 diabetic mice had disorders
in both glucose and lipid metabolism. Glucose metabo-
lism in diabetic mice was insufficient, which could
relieve the suppression of lipolysis. The lack of suppres-
sion of lipolysis increased the influx of fatty acids to the
liver, leading to increased free fatty acid and triglyceride
levels in the liver (table 2). The peripheral fat storage
was then consumed, and the liver weight and relative
liver weight increased. After large amounts of FFAs
enter the liver, b-oxidation of fatty acids was stimulated,
further inhibiting glycolysis [32]. Moreover, evidence
showed that high levels of FFA could stimulate gluco-
neogenesis. At the same time, increased FFA and TG
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Although the activity of CPT-1, which is the rate-limit-
ing enzyme in fatty acid oxidation, was elevated when
large amounts of FFA enter the liver [11], the deficiency
of LC in type 2 diabetes limits its activity. Therefore, the
activity of CPT-1 is not sufficient to handle the elevated
transport of fatty acids into the liver. All of these factors
lead to excess accumulation of hepatic fat, including
FFAs and TGs [34]. It was reported that TG stored in
non-adipocyte cells led to cellular damage as a result of
their lipotoxicity [35]. This process is shown in Figure 4.
The effects of LC
LC plays a critical role in fatty acid oxidation of energy
regulation [36,37]. It serves as a carrier to facilitate the
transport of long-chain fatty acids through the mito-
chondrial membrane and to undertake free fatty acid
b-oxidation. Experimental evidence suggested that this
step is a rate-limiting step in fatty acid oxidation.
Diabetic mice had decreased liver LC levels (table 2),
which is consistent with a previous study in which dia-
betic rats had significantly lower serum and liver LC
levels than normal rats [38]. Administrating LC through
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Figure 2 LC’s effect on liver sections stained by oil red O (×100 times). a, Oil red O images A. control group, B. diabetic group, C.
preventive group, D. high-dose therapeutic group, E. low-dose therapeutic group. Red points in the image indicate lipid droplets stained by oil
red O. b, Lipid profile area percentage Control+NS: control group (n = 3), DM+NS: diabetic group (n = 5), pre-treat: preventive group (n = 5),
DM+LC (H): high-dose therapeutic group (n = 3), DM+LC (L): low-dose therapeutic group (n = 6). All values are expressed as the mean ± S.E.
using the repeated measures method. **P < 0.01 (compared to control group),
##P < 0.01 (compared to diabetic group).
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the liver. As a result, fatty acid b-oxidation increased
[39], and lipid accumulation in the liver decreased. Ele-
vation of fatty acid b-oxidation decreased fat synthesis.
Therefore, the amount of TG transported from the
liver into the plasma decreased. Plasma insulin concen-
trations were significantly elevated after different doses
of LC, which is consistent with other studies in our
lab. A previous study showed that insulin inhibited the
activity of HSL (hormone-sensitive triglyceride lipase),
the key enzyme in lipolysis (Figure 4). Therefore, the
amount of FFAs transported from the peripheral fat to
the liver decreased. In this way, the decrease in body
weight in diabetic mice could be prevented. It is inter-
esting to note that if LC was administrated before the
mice developed diabetes, it prevented weight gain in
diabetic mice from an early stage. This indicates that
the obesity burden could be prevented. Therefore, pre-
ventive administration of LC to high-calorie diet-trea-
ted mice maintained the energy balance and resisted
the effect of STZ. Overall, LC helped lighten the bur-
den of the liver and improve the symptoms of NAFLD
caused by type 2 diabetes. LC could also relieve the
harm of high TG levels to the cardiovascular system
and could therefore be beneficial to diabetic patients.
Moreover, when body weight and liver lipid concentra-
tions were controlled at relatively low levels, blood glu-
cose levels were low in mice in the pre-treatment
group (≤12 mmol/L). This helped mice fed a high-
Figure 3 Effect of LC on the liver by electron microscopy (×30K). A. control group, B. diabetic group, C. preventive group, D. high-dose
therapeutic group, E. low-dose therapeutic group. Mitochondrial (®), glycogen granules (↓), rough endoplasmic reticulum (¬)
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should be administrated in the early stages of diabetes.
Our study revealed that the ratio of LC to ALC
decreased in the liver after LC administration even if
both LC and ALC levels were markedly increased,
which has not been observed before. According to a
previous study, LC increases the CoA/acetyl-CoA ratio
in the mitochondria by converting to ALC through the
activity of CAT [12,13]. This process demonstrated
that LC acted as a carrier of acetyl groups from the
mitochondria to the cytosol [15,19]. In our study, ALC
levels increased more in the high-dose treatment
group, but LC concentrations in the low-dose thera-
peutic group were much higher than in the high-dose
group. This result confirmed our hypothesis that exo-
genous LC supplements could shift the balance of LC
+a c e t y l - C o A⇌ ALC+ CoA to the right. Therefore, the
concentrations of ALC and CoA were elevated. Pre-
vious data have shown that CoA was required for b-
oxidation and other energy metabolism pathways [16].
Therefore, LC helped to decrease the accumulation of
acetyl-CoA in the mitochondrial matrix. For this rea-
son, both glucose and lipid metabolism could be sti-
mulated. In another study, excessive acetyl-CoA was
the substrate of lipogenesis [40]. Therefore, LC could
also inhibit TG produce in liver by decreasing acetyl-
CoA levels. Furthermore, plasma TG transported from
liver was decreased.
Liver function improvement
Disorders such as liver disease, defects in fatty acid
metabolism, and the administration of pharmacological
agents (e.g., pivampicillin or valproic acid) can cause
secondary LC deficiency [41,42]. In our study, elevated
FFA and TG accumulation causes lipotoxicity in hepato-
cytes, which could disrupt liver function. Mitochondrial
dysfunction due to oxidative damage was previously
detected in type 2 diabetes [21]. This dysfunction
Blood Extrahepatic lipocyte
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CAT
CPT-2
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FFA
+
ALC
TG
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Figure 4 Effect of LC on lipid metabolism in the liver and peripheral adipocytes in STZ-treated mice. Acyl-CoA: long chain acyl CoA, CPT-
1: carnitine palmitoyltransferase-1, CAT: carnitine/acylcarnitine translocase, HSL: hormone-sensitive lipase.
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Page 8 of 10referred to a loss of capacity to synthesize LC and other
proteins such as apolipoprotein and other useful factors.
This aggravated damage to the liver and other organs.
Exogenous administration of LC could compensate for
this deficiency, which led to a beneficial cycle. Recently,
DA Rossignol and colleagues used LC as a mitochon-
drial biomarker [20]. LC was indicated to be an essential
factor in maintaining mitochondrial function. LC helped
restore protein synthesis in mitochondrial membranes
and showed an anti-oxidative effect [21,43]. The protec-
tive effect of LC on mitochondria was confirmed mor-
phologically by EM (Figure 3). In conclusion, LC had an
important mitochondrial detoxification effect on hepato-
c y t e sa n do t h e rc e l l s[ 4 1 ] .I ti m p r o v e ds y m p t o m so f
NAFLD and might improve metabolic conditions in
type 2 diabetes mellitus.
Conclusions
Type 2 diabetes induced by a high-calorie diet and two
low-dose STZ injections in mice resulted in decreased
liver LC contents. LC supplements improved mitochon-
drial function in the liver by accelerating the transport
of free fatty acids into the mitochondria and regulating
the matrix ratio of LC to ALC. LC might be an effective
liver protective medicine for delaying the progression of
type 2 diabetes mellitus complications.
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